Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) insider Brian Elsbernd sold 62,975 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the completion of the sale, the insider now directly owns 188,564 shares of the company's stock, valued at $4,333,200.72. This trade represents a 25.04 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Catalyst Pharmaceuticals Price Performance
CPRX stock opened at $21.89 on Thursday. The firm has a market cap of $2.66 billion, a price-to-earnings ratio of 18.55, a PEG ratio of 3.31 and a beta of 0.80. Catalyst Pharmaceuticals, Inc. has a 1-year low of $14.47 and a 1-year high of $24.64. The firm has a fifty day moving average price of $22.27 and a two-hundred day moving average price of $21.49.
Wall Street Analyst Weigh In
A number of equities research analysts recently weighed in on CPRX shares. StockNews.com raised shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, February 28th. Baird R W upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Monday, February 3rd. Stephens reaffirmed an "overweight" rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Truist Financial raised their price target on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a "buy" rating in a research report on Monday, November 11th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $35.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $32.50.
Read Our Latest Stock Report on Catalyst Pharmaceuticals
Institutional Investors Weigh In On Catalyst Pharmaceuticals
A number of institutional investors have recently modified their holdings of the business. JPMorgan Chase & Co. boosted its stake in Catalyst Pharmaceuticals by 9.1% in the third quarter. JPMorgan Chase & Co. now owns 408,261 shares of the biopharmaceutical company's stock valued at $8,116,000 after acquiring an additional 33,888 shares during the period. Allspring Global Investments Holdings LLC grew its stake in Catalyst Pharmaceuticals by 13.9% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 417,332 shares of the biopharmaceutical company's stock worth $8,710,000 after buying an additional 50,888 shares during the last quarter. Wellington Management Group LLP acquired a new stake in Catalyst Pharmaceuticals in the third quarter worth $1,185,000. Redhawk Wealth Advisors Inc. bought a new stake in Catalyst Pharmaceuticals in the fourth quarter valued at $1,273,000. Finally, Spire Wealth Management grew its position in shares of Catalyst Pharmaceuticals by 1,342.9% during the fourth quarter. Spire Wealth Management now owns 14,429 shares of the biopharmaceutical company's stock worth $301,000 after acquiring an additional 13,429 shares during the last quarter. Institutional investors own 79.22% of the company's stock.
About Catalyst Pharmaceuticals
(
Get Free Report)
Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
